FDA Uneasy About Long-Form Zyprexa Side Effect

Law360, New York (February 4, 2008, 12:00 AM EST) -- The bad news continues to pile up for Eli Lilly & Co., with the U.S. Food and Drug Administration issuing a word of caution about the excessive sedation connected to a long-form version of the company's popular schizophrenia drug Zyprexa.

On Monday, the FDA posted an analysis of Zyprexa Adhera, revealing a mixed bag regarding the effectiveness and potential side effects of the injectable formulation.

“FDA agrees that the sponsor has shown that Olanzapine Depot is effective in both the acute and maintenance treatment of schizophrenia,”...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.